Category: MassDevice Q&A
Former Medtronic CEO Bill Hawkins, in an exclusive interview with MassDevice.com, tells us about the one that got away: Guidant Corp.'s stent-making operation.
There's no shortage of ink spilled over the feeding frenzy over Guidant Corp., which ended in Boston Scientific Corp.'s (NYSE:BSX) ill-fated $26 billion acquisition in 2006. But there's one nugget from the spectacle that hasn't received much attention.
Seasoned patent attorney David Dykeman takes us through the America Invents Act in a podcast interview highlighting the challenges and opportunities the reform bill poses for the medical device industry.
This week President Barack Obama is expected to sign a patent reform bill marking the most dramatic changes to the patent system in decades, drawing adulation and ire from varying sectors of the innovation economy.
The American Invents Act, six years in the making, contains several sweeping changes, but the main bone of contention is a transformation of the U.S. patent system from a first-to-invent application process to a first-to-file process.
Boston Scientific makes a generational move in choosing Johnson & Johnson executive Michael Mahoney, but who is the 46-year-old medical device veteran?
In naming Michael Mahoney as the heir apparent to J. Raymond Elliott, Boston Scientific Corp. (NYSE:BSX) fired another salvo in a long-running blood feud with Johnson & Johnson Corp. (NYSE:JNJ).
Neuronetics president & CEO Bruce Shook on treating an incurable psychiatric disorder, chasing reimbursement and turning psychiatrists into medical device proceduralists.
Neuronetics' NeuroStar TMS therapy system
Neuronetics Inc. is paving the way for a new type of depression therapy, a non-invasive electromagnetic field treatment designed to stimulate brain cells linked to depression.
Bruce Shook, co-founder, president & CEO, talked to MassDevice about pioneering the market for the only FDA-cleared transcranial magnetic stimulation system to date, his company's NeuroStar TMS system.
The therapy, which won the FDA nod in 2008, is a rarity in the med-tech world: A device-based approach to a psychiatric disorder.
Former Medtronic CEO Bill Hawkins, in the second installment of an in-depth interview with MassDevice.com, gives us an inside look at one of the most high-profile medical device recalls ever – the Sprint Fidelis pacemaker lead.
Former Medtronic CEO Bill Hawkins at MassDevice
In October 2007 Bill Hawkins was only three months into his tenure as CEO of the world's largest pure-play medical device maker when he faced the toughest choice of his career – cancel shipment on the company's top product, the Sprint Fidelis pacemaker lead, already implanted in some 268,000 patients – or stand pat and keep the potentially lethal products on the market.
Calypso Medical Techechnologies CEO Ed Vertatschitsch on the company's tumor-tracking radiation therapy, "GPS for the Body," why the company tackled prostate cancer first and what organs may be next.
Calypso Medical Technologies Inc. treated its 10,000th prostate cancer patient with GPS for the Body in May, an important landmark for the Seattle-based targeted radiation therapy company and its flagship device.
GPS for the Body won FDA clearance in 2006 for focused prostate cancer radiation therapy using a proprietary guidance system that tracks a tumor in real time as the body moves, keeping the radiation beam on target.
Former Medtronic CEO Bill Hawkins, in the first installment of an in-depth interview with MassDevice.com, tells us why the time had come for him to leave the world's largest pure-play device maker – and fills us in on his plans for the future.
They gave him a sword and he handed them the world.
When William Hawkins officially flipped the keys to Medtronic Inc. (NYSE:MDT) over to successor Omar Ishrak, he offered a simple message and a gift. The message was clear – don't lose sight of founder Earl Bakken's mission to alleviate pain, restore health and extend life while "striving without reserve for the greatest possible reliability and quality."